170 related articles for article (PubMed ID: 37048053)
1. S1P1 Threonine 236 Phosphorylation Mediates the Invasiveness of Triple-Negative Breast Cancer and Sensitivity to FTY720.
Laroche FJF; Li S; Shen N; Hwang SK; Nguyen G; Yu W; Wong CK; Quinton RJ; Berman JN; Liu CT; Singh A; Ganem NJ; Thiagalingam S; Feng H
Cells; 2023 Mar; 12(7):. PubMed ID: 37048053
[TBL] [Abstract][Full Text] [Related]
2. Activation of S1P₁ receptor regulates PI3K/Akt/FoxO3a pathway in response to oxidative stress in PC12 cells.
Safarian F; Khallaghi B; Ahmadiani A; Dargahi L
J Mol Neurosci; 2015 May; 56(1):177-87. PubMed ID: 25534920
[TBL] [Abstract][Full Text] [Related]
3. FTY720 prevents ischemia/reperfusion injury-associated arrhythmias in an ex vivo rat heart model via activation of Pak1/Akt signaling.
Egom EE; Ke Y; Musa H; Mohamed TM; Wang T; Cartwright E; Solaro RJ; Lei M
J Mol Cell Cardiol; 2010 Feb; 48(2):406-14. PubMed ID: 19852968
[TBL] [Abstract][Full Text] [Related]
4. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
Brinkmann V
Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
[TBL] [Abstract][Full Text] [Related]
5. Regulation of endothelial nitric oxide synthase activation in endothelial cells by S1P1 and S1P3.
Tölle M; Klöckl L; Wiedon A; Zidek W; van der Giet M; Schuchardt M
Biochem Biophys Res Commun; 2016 Aug; 476(4):627-634. PubMed ID: 27282481
[TBL] [Abstract][Full Text] [Related]
6. Immunosuppressive and anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce ubiquitinylation and proteasomal degradation of the receptor.
Oo ML; Thangada S; Wu MT; Liu CH; Macdonald TL; Lynch KR; Lin CY; Hla T
J Biol Chem; 2007 Mar; 282(12):9082-9. PubMed ID: 17237497
[TBL] [Abstract][Full Text] [Related]
7. FTY720 (Fingolimod) attenuates basal and sphingosine-1-phosphate-evoked thyroid cancer cell invasion.
Kalhori V; Magnusson M; Asghar MY; Pulli I; Törnquist K
Endocr Relat Cancer; 2016 May; 23(5):457-68. PubMed ID: 26935838
[TBL] [Abstract][Full Text] [Related]
8. Pulmonary endothelial cell barrier enhancement by FTY720 does not require the S1P1 receptor.
Dudek SM; Camp SM; Chiang ET; Singleton PA; Usatyuk PV; Zhao Y; Natarajan V; Garcia JG
Cell Signal; 2007 Aug; 19(8):1754-64. PubMed ID: 17475445
[TBL] [Abstract][Full Text] [Related]
9. AKP-11 - A Novel S1P1 Agonist with Favorable Safety Profile Attenuates Experimental Autoimmune Encephalomyelitis in Rat Model of Multiple Sclerosis.
Samuvel DJ; Saxena N; Dhindsa JS; Singh AK; Gill GS; Grobelny DW; Singh I
PLoS One; 2015; 10(10):e0141781. PubMed ID: 26513477
[TBL] [Abstract][Full Text] [Related]
10. Morpholino Analogues of Fingolimod as Novel and Selective S1P
Stepanovska B; Zivkovic A; Enzmann G; Tietz S; Homann T; Kleuser B; Engelhardt B; Stark H; Huwiler A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899717
[TBL] [Abstract][Full Text] [Related]
11. S1P Stimulates Erythropoietin Production in Mouse Renal Interstitial Fibroblasts by S1P
Hafizi R; Imeri F; Wenger RH; Huwiler A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502385
[TBL] [Abstract][Full Text] [Related]
12. Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain.
Singh SK; Spiegel S
Adv Biol Regul; 2020 Jan; 75():100670. PubMed ID: 31708456
[TBL] [Abstract][Full Text] [Related]
13. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
[TBL] [Abstract][Full Text] [Related]
14. Triple Negative Breast Cancer Depends on Sphingosine Kinase 1 (SphK1)/Sphingosine-1-Phosphate (S1P)/Sphingosine 1-Phosphate Receptor 3 (S1PR3)/Notch Signaling for Metastasis.
Wang S; Liang Y; Chang W; Hu B; Zhang Y
Med Sci Monit; 2018 Apr; 24():1912-1923. PubMed ID: 29605826
[TBL] [Abstract][Full Text] [Related]
15. Non-phosphorylated FTY720 induces apoptosis of human microglia by activating SREBP2.
Yoshino T; Tabunoki H; Sugiyama S; Ishii K; Kim SU; Satoh J
Cell Mol Neurobiol; 2011 Oct; 31(7):1009-20. PubMed ID: 21519925
[TBL] [Abstract][Full Text] [Related]
16. Phosphorylation of the immunomodulator FTY720 inhibits programmed cell death of fibroblasts via the S1P3 receptor subtype and Bcl-2 activation.
Potteck H; Nieuwenhuis B; Lüth A; van der Giet M; Kleuser B
Cell Physiol Biochem; 2010; 26(1):67-78. PubMed ID: 20502006
[TBL] [Abstract][Full Text] [Related]
17. Sphingosine-1-Phosphate Induces Dose-Dependent Chemotaxis or Fugetaxis of T-ALL Blasts through S1P1 Activation.
Messias CV; Santana-Van-Vliet E; Lemos JP; Moreira OC; Cotta-de-Almeida V; Savino W; Mendes-da-Cruz DA
PLoS One; 2016; 11(1):e0148137. PubMed ID: 26824863
[TBL] [Abstract][Full Text] [Related]
18. S1P analogues SEW2871, BAF312 and FTY720 affect human Th17 and Treg generation ex vivo.
Zehra Okus F; Busra Azizoglu Z; Canatan H; Eken A
Int Immunopharmacol; 2022 Jun; 107():108665. PubMed ID: 35255303
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015).
Guerrero M; Urbano M; Roberts E
Expert Opin Ther Pat; 2016; 26(4):455-70. PubMed ID: 26947494
[TBL] [Abstract][Full Text] [Related]
20. FTY720 and two novel butterfly derivatives exert a general anti-inflammatory potential by reducing immune cell adhesion to endothelial cells through activation of S1P(3) and phosphoinositide 3-kinase.
Imeri F; Blanchard O; Jenni A; Schwalm S; Wünsche C; Zivkovic A; Stark H; Pfeilschifter J; Huwiler A
Naunyn Schmiedebergs Arch Pharmacol; 2015 Dec; 388(12):1283-92. PubMed ID: 26267293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
